Metanoia Press · In preparation
Iboga is unlike anything else in the family. Its journey can last more than a day, its character is dreamlike rather than visionary, and its most striking claim is against addiction — reports of interrupting opioid dependence that have drawn serious scientific attention. It also carries a real cardiac risk that must be respected. Our forthcoming book holds the promise and the danger in the same frame, and roots both in the Central African tradition that has used it for generations.
What the Book Will Cover
Tabernanthe iboga of Gabon, its root bark, and its principal alkaloid, ibogaine, with its long-acting metabolite noribogaine.
The Central African spiritual tradition — initiation and community ritual — for which iboga is a sacrament, not a drug.
Why an "atypical" psychedelic that raises BDNF and GDNF has drawn attention for interrupting opioid dependence.
The heart-rhythm danger that makes medical screening and monitoring non-negotiable.
Ibogaine acts on an unusually broad set of targets — NMDA, opioid, sigma, and serotonin systems — and raises the growth factors BDNF and GDNF, connecting it to the same neuroplasticity thread that runs across the family, even though its subjective character is closer to a long dream than a classic "trip." A 2024 study of magnesium-buffered ibogaine in special-operations veterans with traumatic brain injury, published in a leading medical journal, reported improvements in PTSD, depression, and functioning — the magnesium included specifically to protect the heart.
Ibogaine can dangerously prolong the heart's QT interval, and deaths have occurred in unmonitored settings. This is why serious clinical work uses cardiac screening, monitoring, and measures like magnesium buffering — and why iboga is emphatically not something to approach casually. "Natural" is not the same as "safe."
The addiction-interruption signal is real enough that the field is investing heavily in it, but rigorous randomized trials remain scarce. We report it as what it is: genuinely promising, genuinely serious, and not yet settled.
Reliability: pharmacology and cardiac risk are well established (strong); efficacy evidence is early, mostly observational (limited). Full sources will accompany the finished book.